ICON PLC (ICLR)

Currency in USD
151.82
-0.42(-0.28%)
Closed·
151.820.00(0.00%)
·
ICLR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
150.32156.20
52 wk Range
66.57211.00
Key Statistics
Prev. Close
151.82
Open
152.93
Day's Range
150.32-156.2
52 wk Range
66.57-211
Volume
1.22M
Average Volume (3m)
1.17M
1-Year Change
4.8988%
Book Value / Share
120.4
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ICLR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
153.25
Upside
+0.94%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

ICON PLC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Analyst Ratings

8 Buy
8 Hold
1 Sell
Ratings:
17 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 153.25
(+0.94% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
TD Cowen
Buy164.00+8.02%120.00Maintain01/06/2026
BofA Securities
Sell125.00-17.67%105.00Maintain01/06/2026
RBC Capital
Hold126.00-17.01%123.00Maintain29/05/2026
Barclays
Hold150.00-1.20%120.00Maintain29/05/2026
Leerink
Hold145.00-4.49%125.00Maintain28/05/2026

ICON PLC SWOT Analysis


CRO Market Dynamics
Explore ICON's navigation of industry challenges, including bookings volatility and demand uncertainties in the competitive CRO landscape
Financial Resilience
Delve into ICON's solid financial health, with EPS forecasts of $13.40 (FY1) and $14.06 (FY2), despite recent market pressures
Strategic Positioning
Learn how ICON leverages proprietary technology and global scale to capture high-quality opportunities in a shifting pharmaceutical landscape
Valuation Insights
Analysts set price targets ranging from $155 to $263, suggesting potential for value realization as transient headwinds subside
Read full SWOT analysis

ICON PLC Earnings Call Summary for Q4/2025

  • ICON plc Q4 2025 revenue hit $2.1B, beating estimates by 7.65%, though EPS of $2.52 missed forecasts by 16%, falling short of $3.00 target.
  • Adjusted EBITDA margin compressed to 15.5% with gross margin declining to 23.7% from 30.9% YoY, reflecting significant profitability pressures.
  • Company disclosed investigation into revenue recognition practices; stock rose 6.57% pre-market on strategic AI integration and lab expansion plans.
  • Management projects 19% effective tax rate for 2026, emphasizing AI and precision medicine initiatives as growth drivers amid CRO industry headwinds.
  • Seven analysts revised earnings downward for upcoming periods; CEO Cutler cited strategic partnerships and Symphony Health divestiture to support innovation.
Last Updated: 28/05/2026, 14:36
Read Full Transcript

Earnings

Latest Release
27/05/2026
EPS / Forecast
2.52 / 3.00
Revenue / Forecast
2.11B / 1.96B
EPS Revisions
Last 90 days

Compare ICLR to Peers and Sector

Metrics to compare
ICLR
Peers
Sector
Relationship
P/E Ratio
50.7x23.2x−0.5x
PEG Ratio
−0.75−1.130.00
Price/Book
1.3x2.7x2.6x
Price / LTM Sales
1.4x2.4x3.0x
Upside (Analyst Target)
2.1%22.5%58.6%
Fair Value Upside
Unlock21.6%10.2%Unlock

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
42.58M55.61%6.46B
Other Institutional Investors
39.87M44.39%6.05B
Public Companies & Retail Investors
0.000.00%0.00
Total
82.44M100.00%12.52B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Artisan Partners Limited Partnership10.81%8,278,9451,260,387
Wellington Management Group LLP7.72%5,913,037900,201

People Also Watch

229.19
JAZZ
-1.23%
71.64
TMHC
+0.28%
1,225.15
FICO
+1.48%
234.32
CRDO
+5.42%
920.15
GEV
-1.47%

FAQ

What Is the ICON PLC (NASDAQ: ICLR) Share Price Today?

The ICON PLC stock price today is 151.82 USD.

What Stock Exchange Does ICON PLC (ICLR) Trade On?

ICON PLC is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for ICON PLC?

The stock symbol (also called a 'ticker') for ICON PLC is "ICLR."

What Is the Current ICON PLC Market Capitalisation?

As of today, ICON PLC (NASDAQ: ICLR) market cap is 11.62B USD.

What Is ICON PLC's (ICLR) Earnings Per Share (TTM)?

The ICON PLC EPS is currently 2.90 (Trailing Twelve Months).

When Is the Next ICON PLC Earnings Date?

ICON PLC's next earnings report will be released on 29/07/2026.

Is ICLR a Buy or Sell From a Technical Analyst Perspective?

Based on today's ICON PLC moving averages and other technical indicators, the daily buy/sell signal for ICLR stock is Strong Buy.

How Many Times Has ICON PLC Stock Split?

ICON PLC has split 2 times. (See the ICLR stock split history page for full effective split date and price information.)

How Many Employees Does ICON PLC Have?

ICON PLC has 40100 employees, based on their latest Companies House report.

What is the current trading status of ICON PLC (NASDAQ: ICLR)?

As of 10/06/2026, ICON PLC (ICLR) is trading at a share price of 151.82 USD, with a previous close of 151.82 USD. The stock has fluctuated within a day range of 150.32 USD to 156.20 USD, while its 52-week range spans from 66.57 USD to 211.00 USD.

What Is ICON PLC (ICLR) Price Target According to Analysts?

The average 12-month price target for ICON PLC is 153.25 USD, with a high estimate of 180 USD and a low estimate of 125 USD. 8 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +0.94% Upside potential.

What Is the ICLR Premarket Price?

ICLR's last pre-market stock price is 151.64 USD. The pre-market share volume is 50.00, and the stock has decreased by -0.60, or -0.39%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.